Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Shanghai, China.
J Gynecol Oncol. 2022 Nov;33(6):e86. doi: 10.3802/jgo.2022.33.e86.
Over the last decade, clinical trials using various poly ADP ribose polymerase (PARP) inhibitors on patients with ovarian cancer have shown promising results. The introduction of PARP inhibitors has changed the treatment landscape and improved outcomes for patients with ovarian cancer. Fuzuloparib, developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., is a novel orally available small molecule PARP inhibitor. By introducing the trifluoromethyl group into chemical structure, fuzuloparib exhibits higher stability and lower inter-individual variability than other PARP inhibitors. Several clinical trials (FZOCUS series and others) have been carried out to assess the efficacy and safety of fuzuloparib through different lines of treatments for advanced or recurrent ovarian cancer in both treatment and maintenance. Here, we present the most recent data from these studies, discuss current progress and potential future directions.
在过去的十年中，针对卵巢癌患者的各种多聚 ADP 核糖聚合酶 (PARP) 抑制剂的临床试验取得了可喜的结果。PARP 抑制剂的引入改变了卵巢癌的治疗格局，改善了患者的预后。由江苏恒瑞医药有限公司开发的氟唑帕利是一种新型口服小分子 PARP 抑制剂。通过在化学结构中引入三氟甲基，氟唑帕利比其他 PARP 抑制剂具有更高的稳定性和更低的个体间变异性。几项临床试验（FZOCUS 系列和其他）已经开展，通过不同的治疗线评估氟唑帕利在晚期或复发性卵巢癌中的疗效和安全性，包括治疗和维持治疗。在这里，我们呈现了这些研究的最新数据，讨论了当前的进展和潜在的未来方向。
